



Brilliance in photodynamic technology™

Photocure Capital Markets Day R&D pipeline

5 June 2007

Proven track record

– 2 products approved in 10 years



Metvix

IP from The Radium Hospital in 1997

EU approval 2001
US approval 2004

Hexvix

IP from University of Lausanne in 2000

EU approval 2005

How

Very competent internal expertise and management

Carefully selected partners and CROs with commitment

Active collaboration with advisors and KOLs

Communication with regulatory authorities

R&D status today



What

3 projects in clinical phase

PCI Biotech starting clinical phase in 2007

Supporting Hexvix and Metvix with phase IV studies

Preparing sNDA for Aktlite in the US

Follow-up of Hexvix NDA in the US

Exploratory and IP

Why

Leverage the unique technology platform

Large unmet medical need for our products

Large market potential for our products

Opportunity for organic growth of Photocure

We can do it!

Photocure PDT is unique



Selective treatment of lesions

- Surrounding tissue preserved
- No systemic or long lasting side effects

Proof: Metvix Complete response rates 91 -93%
3 months after treatment

Metvix Recommended in guidelines for
treatment of AK, BCC and Bowens disease

Diagnosis of cancer improved

Proof: Hexvix Detects 30 % new patients with CIS
Detects 67 % new lesions
Improves management in 1 in 5 patients

Hexvix Recommended in EU guidelines for
diagnosis of bladder cancer

Strong Patent protection

11 patent families ; Use, methods and substances


Photocure develops its patented PDT for new market opportunities

PDT


- a combination of drug and light



Example – treatment with Metvix



1. Tumour cells accumulate phototactive porphyrins (PAPs) and become sensitive to light
2. Illumination with Aktelite generates singlet oxygen species
3. The tumour cells are destroyed, while healthy tissue remains unharmed




Fluorescence shows that the application of Metvix leads to selective porphyrin accumulation in diseased tissue

PDT – an increasing modality



PDT is accepted in the market and is a growing modality

The number of scientific publications with PDT has increased




Photocure has 2 of 6 approved products

Strong Pipeline in Clinical Phase



Acne	Treatment of moderate to severe acne <i>Current treatments limited efficacy or severe side effects</i>
HPV	Treatment of HPV induced disease in cervix <i>Medical need for an alternative to conisation</i>
Colon	Diagnosis of colon cancer <i>Early diagnosis improves survival</i> <i>Need to improve current colonoscopy</i>
PCI	Drug Delivery System (DDS) Targeting drug internalisation <i>Improve efficacy and reduce side effects of known compounds</i> <i>Medical need for novel delivery methods for genes, ex siRNA</i>

Turning the pipeline into value - opportunities for licensing/co-development



Photocure will capture the R&D value by partnering up

This document was created with Win2PDF available at <http://www.win2pdf.com>.
The unregistered version of Win2PDF is for evaluation or non-commercial use only.